Regulatory Affairs: A Compliance Career Path Getting Medical Products to Market

A mid-size device company finishes validation testing on a new insulin pump three weeks before its planned launch, and the regulatory affairs lead reviews the software change log one more time before submitting the update to the FDA. Buried in the log is a firmware change that wasn't in the original 510(k) submission: a new alarm threshold the engineering team added late in development to address a usability complaint from testing. It's a small change, and clinically it makes the device safer. But it also means the cleared device and the device about to ship aren't the same device on paper, and shipping it as-is would mean marketing a modification without the clearance that covers it. The regulatory affairs lead now has to make a call that has nothing to do with engineering and everything to do with risk: does this change require a new 510(k), a letter to file documenting why it doesn't, or something in between — and can that decision be defended if the FDA ever asks. That judgment, repeated across submissions, labeling, and post-market changes for the life of a product, is what regulatory affairs actually is.

What regulatory affairs is, and what it isn't

Regulatory affairs sits between the people who build a product and the agencies that decide whether it can be sold. It is not clinical research, which designs and runs the studies that generate safety and efficacy data. It is not quality assurance, which builds and audits the manufacturing and design controls the product is built under. And it is not general legal or compliance, which handles contracts, employment, and broader corporate risk. Regulatory affairs translates a product's technical and clinical evidence into the specific dossier a specific regulator requires, chooses the fastest defensible pathway to get there, and manages the relationship with the regulator for the life of the product — not just at launch.

The reason this is its own career track rather than a subset of quality or clinical work is that regulatory strategy has to be decided early, before most of the expensive work happens. Whether a device will need a 510(k) clearance or a more demanding Premarket Approval (PMA), or whether a drug can go through an Abbreviated New Drug Application (ANDA) instead of a full New Drug Application (NDA), changes the entire development timeline and budget. A company that gets this call wrong doesn't just delay a submission — it can spend two years and tens of millions of dollars building evidence for the wrong pathway.

What the work actually involves

The center of the job is the submission itself, but the submission is the output of a much longer process:

• **Pathway and strategy determination.** Before a submission is drafted, someone has to decide which regulatory pathway applies, based on the product's risk classification, its similarity to products already on the market, and the specific requirements of each jurisdiction the company wants to sell into. This decision shapes what clinical and technical evidence needs to exist before filing.
• **Assembling the submission.** For a device, this might mean a 510(k) demonstrating substantial equivalence to a predicate device already on the market, or a PMA for higher-risk devices with no predicate, built around a full technical file: design specifications, risk analysis, biocompatibility and performance testing, software documentation, and proposed labeling. For a drug, it means compiling the Common Technical Document (CTD) — nonclinical, clinical, and manufacturing data organized in the format regulators expect.
• **Managing agency correspondence.** Regulators respond to submissions with questions, requests for additional data, or formal deficiency letters. Regulatory affairs drafts the responses, coordinates whatever additional testing or analysis is needed, and tracks the clock — many pathways have review timelines that reset or extend depending on how a response is handled.
• **Labeling.** Every claim on a label — indication, dosage, warnings, contraindications — has to be supported by the evidence in the submission and match what the regulator actually cleared or approved. A label that oversells what the data supports is one of the most common reasons for a warning letter after launch.
• **Change control and post-market management.** Once a product is on the market, almost every meaningful change — a manufacturing site change, a formulation tweak, a new software version, a new indication — triggers a decision about whether it needs a new submission, a supplement, or can go through a lower-burden notification. This is where the insulin pump firmware question above lives, and it's a recurring, not a one-time, part of the job.
• **Adverse event and post-market surveillance obligations.** Regulatory affairs typically owns or coordinates the reporting timelines for adverse events, device malfunctions, and recalls, which in the US and EU carry specific, short reporting windows that don't bend for internal process delays.

The regulatory frameworks that structure the work

In the United States, the FDA classifies medical devices into three classes by risk (Class I, II, III), which determines whether a 510(k), a PMA, or in some cases no premarket submission at all is required; drugs go through the Investigational New Drug (IND) process into clinical trials and then an NDA or, for generics, an ANDA relying on an already-approved reference product. In the European Union, the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), both fully in force since their respective transition deadlines, replaced the older, looser Medical Device Directive framework with more demanding clinical evidence and post-market surveillance requirements — a shift that pushed many companies to expand their regulatory affairs teams specifically to handle MDR technical file remediation for products that had been on the market for years under the old rules. Beyond the US and EU, the International Council for Harmonisation (ICH) publishes guidelines that pharmaceutical regulators in multiple regions have adopted, which is why a regulatory affairs professional working on drugs quickly learns ICH terminology regardless of which specific country's agency they're filing with.

A regulatory affairs professional doesn't need to master every jurisdiction. Most people specialize by product type (devices, drugs, biologics, combination products) and by region, and build breadth over a career rather than starting with it.

How people actually get into it

There is no single entry door, but three paths show up most often. The first is a life sciences or engineering degree followed by a role in quality, clinical research, or manufacturing, with a lateral move into regulatory affairs once the person understands how the product is actually built and tested — many hiring managers prefer this path because regulatory strategy is easier to learn on top of product knowledge than the reverse. The second is an entry-level regulatory affairs associate or coordinator role directly out of school, usually at a larger company with a structured training program, doing submission formatting and document control before taking on strategy. The third is a move from a regulatory agency itself — a former FDA reviewer, for instance, brings direct knowledge of how submissions are actually evaluated internally, which is valuable enough that agency experience is a recognized, if less common, entry path at the senior end.

Entry-level titles to search for include regulatory affairs associate, regulatory affairs coordinator, and regulatory affairs specialist. A background in biology, chemistry, biomedical engineering, nursing, or pharmacy helps you get past the first screen, but what actually gets you the offer is evidence you can read a technical requirement and translate it into a document plan — the same skill the job requires for the rest of a career.

Certifications worth having

The Regulatory Affairs Certification (RAC), administered by the Regulatory Affairs Professionals Society (RAPS), is the credential most consistently recognized in this field, offered in tracks for US, EU, and other jurisdictions and requiring a minimum amount of work experience before you can sit for it. It isn't usually required for entry-level roles, but it signals depth of knowledge and shows up as a preferred qualification in job postings for regulatory affairs manager and above. Beyond RAC, industry-specific training — an ISO 13485 (medical device quality management systems) awareness course, or ICH GCP training if you work near clinical trials — rounds out the credential most regulatory affairs professionals build over the first several years, though none of it substitutes for the experience of having actually taken a submission through a full review cycle.

Where the career goes

The near-term progression runs from associate to specialist to regulatory affairs manager, where you own submission strategy for a product line rather than executing individual filings. From there, paths split: some move toward regulatory affairs director or VP roles managing a global portfolio and a team of specialists by region; others move into regulatory intelligence or policy roles, tracking how regulations are changing and advising a company on how to prepare before a rule takes effect rather than after; a smaller group moves into consulting, advising multiple companies through submissions, or crosses into a regulatory agency itself later in a career, bringing industry experience to a reviewer role. At every level, the through-line is the same judgment call the regulatory affairs lead made on the insulin pump: deciding what a change actually requires under the rules as written, and being able to defend that decision on paper long after the product has shipped.